University of Delaware
BIOLOGY & MEDICINE
University of Delaware
Office of Economic Innovation
& Partnerships
1 Innovation Way, Suite 500
Delaware Technology Park
Newark, DE 19711
Ph: (302) 831-4005
techtransfer@udel.edu
Version: 14.2
1
List of Technologies
Page No.
Title
Case
Number
1
Novel Polypeptides That Assist in in Vitro Cellular Adhesion
UD01-01
2
Molecular Tool for Detection of Prox 1 Proteins
(Markers for the Lymphatic System)
UD05-08
3
Drug Delivery System for Long Term Release of Biologically
Active Agents
UD05-17
UD06-29
4
Novel Approach for Detecting the Activities of Protein Kinases
UD06-27
5
New Class of Anti-Androgens for Prostate Cancer
UD06-35
UD09-32
6
Method to Isolate Peptide from Whey and Milk
UD07-33
7
Novel Tool for Detection of Metastatic Cancer
UD07-34
8
Novel Means for Tyrosine Phosphatase/Kinase Detection in
Therapeutic Application
UD10-35
9
Novel Use of Regulatory Platelets for Anti-Thrombotic Drug
UD11-19
10
Novel Tool for Enhanced Recombinant Protein Production
UD11-20
11
Injectable and Biologically Derived Polymer for Tissue Repair
UD11-38
List of Technologies
Page No.
Title
Case
Number
12
Hydrogel Based Slow Release Drug Delivery Vehicle
UD12-10
13
Fast and Low Cost Method for DNA Sequencing
UD12-17
14
Salivary Gland Restoration
UD12-39
15
Novel Probes With Enhanced Specificity and Sensitivity in
Magnetic Imaging Applications (NMR, MRS, MRI)
UD13-15
16
Sensole Shoe: A Device for Measuring Gait in Parkinson’s
Disease Patients
UD13-30
17
Modular Steering and Braking System for Commercial Bicycle
or Tricycle
UD13-42
18
Sit-Stand-Power Walker for Early-Aged Developing Children With
Mobility Impairments
UD13-47
19
VidaVest: A Chest Compression Simulation Device for Improved
Cardiopulmonary Resuscitation Training
UD14-06
20
Tracheostomy Overlay for Educational Simulation
UD14-07
21
QuadCrew Recoil Rowing System
UD14-09
22
Activity-Based Diubiquitin Probes for Elucidating the Linkage
Specificity of Deubiquitinating Enzymes
UD14-21
List of Technologies
Page No.
Title
Case
Number
23
QuadCrew Seat Motion Syncing Straps
UD14-25
24
QuadCrew Adaptive Rowing Seat for Peron with Physical
Disabilities
UD14-26
25
Playskin™ Lift: Assistive Garments for Young Infants With
Weakness or Movement Problems
UD14-27
26
Multimode Degradable Hydrogels For Controlled Therapeutic
Release
UD14-40
27
IPTB, a novel apoptosis signal-regulating kinase (ASK1) inhibitor
as anti-thrombotic drug
UD14-50
Novel Polypeptides That Assist in in vitro Cellular Adhesion
(UD01-01)
Technology Description:
The invention is directed to a polypeptide derived from domain IV of the extracellular matrix protein
perlecan that can selectively adhere cells, nucleic acids encoding the inventive polypeptide, vectors
comprising the nucleic acids, devices comprising a scaffold coated with the inventive polypeptide, and
methods of adhering cells to a scaffold using the inventive polypeptide. The peptide had applications to in
vitro cellular adhesion, including but not limited to:



Cell culture
Materials coating
Device surface property manipulation
Additional uses of the peptide can manifest in tissue engineering and device delivery objectives.
Fig. Photograph of 10T1/2 cells plated on
plastic coated with the polypeptide of
SEQ ID NO:1
Benefits:
 Peptide sequence is amendable to chemical synthesis
 Supports rapid formation of focal adhesions of mesenchymal stem cells
Patent Status:
The technology is patented with fully preserved U.S. patent rights available for licensing opportunities.
 U.S. Issued Patent (No. 7,897,727)
 U.S. Issued Patent (No. 7,803,905)
1
Molecular Tool for Detection of Prox 1 Proteins
(Markers for the Lymphatic System)
(UD05-08)
Technology Description:
Prox 1 is a protein that appears to regulate the transcription of genes important for the development of
the ocular lens, liver, hair cells of the ear, and the lymphatic system. The invention is comprised of
monoclonal antibodies against Prox1 of vertebrates and two continuous cell lines for their production.
These antibodies are particularly useful in immunoassays to detect the presence of Prox1 protein in
vertebrate tissues and cells. This ability is useful because Prox1 is one of the only known markers of the
lymphatic system that has been proven consistently to tell lymphatic from blood vessels. The technology
should be of interest to firms concerned with hepatocellular carcinomas, and users of other Prox1
immunoassay techniques.
Fig. Immunofluorescence staining of human lense with one manifestation of the monoclonal antibodies.
Benefits:
When compared to existing polyclonal antibodies and cell lines for Prox1, the invention:
 Can be used to prepare greater amounts of uniform antibodies
 Exhibits greater potential to be used as chemical reagents
Patent Status:
The technology is patented with fully preserved U.S. patent rights available for
licensing opportunities.
 U.S. Issued Patent (No. 7,411,049)
2
Drug Delivery System for Long Term Release of
Biologically Active Agents
(UD05-17, UD06-29)
Technology Description:
The present invention relates to a biologically active, functionalized, electrospun matrix to permit
immobilization and long-term delivery of biologically active agents. In particular the invention relates to
a functionalized polymer matrix comprising a matrix polymer, in which the matrix is modified by addition
of a compatibilizing polymer functionalized with a biomolecule or other small functioning molecule.
Examples of active molecules that may be used with the multicomponent polymer of the invention
include, for example, a drug, a biopolymer, a growth factor, a protein, a peptide, a nucleotide, a
polysaccharide, a biological macromolecule or the like. The invention is further directed to the formation
of functionalized crosslinked matrices, such as hydrogels, that are formed by the interactions of at least
one functionalized compatibilizing polymer capable of assembly, and that can be responsive to cellsurface receptors. Applications include injectable or implantable devices that provide sustained drug
delivery (small molecule, peptide, protein, or otherwise) over long timescale, as well as bandages or
gauze that deliver therapeutic agents to a surface.
Fig. Multi-photon microscopy image of electrospun
poly-ethylene-oxide/low molecular weight heparin dye
fibers (5 μm scale bar).
Benefits:
 Lower frequency of dosing
 Improved bioactivity
 Targeted, controlled drug delivery
Patent Status:
The technologies are patented with fully preserved U.S. patent rights available for
licensing opportunities.





U.S. Issued Patent (No. 7,732,427)
U.S. Issued Patent (No. 8,338,390)
U.S. Issued Patent (No. 8,367,639)
U.S. Issued Patent (No. 7,737,131)
U.S. Issued Patent (No.8,415,325)
3
Novel Approach for Detecting the Activities of Protein Kinases
(UD06-27)
Technology Description:
This technology involves the development of an approach to detect the activities of protein kinases.
Protein kinases and phosphatases are two classes of enzyme that modify cellular protein which leads to
changes in regulation and cellular control. Humans have over 500 kinases and 100 phosphatases.
Changes in their activities have been implicated in cancer, Alzheimer’s disease, and heart disease. To
detect the activities of kinases, proteins have been developed whose structures depend on action by a
certain protein kinase. The approach is designed to be applicable to the specific imaging of the activities
of each of the individual protein kinases and phosphatases. The novel breakthrough is usage of
phosphoserine and phosphotheronine to mimic glutamic acid to indicate kinase activity.
Fig. Design of a a phosphorylationdependent motif, indicating the roles of
Glu, Ser, and phosphoserine residues.
Benefits:




Genetically encodable
300-1000% increase in fluorescence, compared to 25% change seen with existing sensors
Genetic encodability and large changes in fluorescence not seen together in current sensors
Method to detect cancerous and pre-cancerous cells
Patent Status:
The technology is patented with fully preserved U.S. patent rights available for
licensing opportunities.
 U.S. Issued Patent (No. 8,003,759)
 U.S. Issued Patent (No. 8,148,506)
4
New Class of Anti-Androgens for Prostate Cancer
(UD06-35 UD09-32)
Technology Description:
This breakthrough technology is based on the development of a unique therapeutic agent (PLM1) and
related derivatives that are antagonists of the human androgen receptor and androgen receptor
mutations associated with clinical failure of currently prescribed anti-androgens used in the treatment of
prostate cancer. While such agents are highly effective at treating naïve tumors, 20-30% of patients
become resistant to such anti-androgen therapy. Currently no effective treatment alternative for
resistant prostate cancer exists. PLM1 and its derivatives have been uniquely designed to target androgen
receptor mutations that are known to impart resistance to anti-androgens currently used in cancer
chemotherapy, and have the potential to delay the occurrence of anti-androgen withdrawal syndrome.
PLM1 and its analogs could serve as a second line of defense in anti-androgen therapy when mutations to
the androgen receptor give rise to anti-androgen withdrawal. Using in vitro screens that mimic drug
resistant forms of prostate cancer, a number of novel compounds have been identified that have the
ability to circumvent the development of resistance to reduce and/or delay the occurrence of antiandrogen resistance in vitro.
Fig. In vitro selections of LnCaP cells with 20 μM
bicalutamide: A. week 1, B. week 4, C. Week20;
20 μM Formula III: D. Week 1, E. Week 4, F.
Week 12; 20 μM Formula VII: G. Week 1, H.
Week 4, I. Week 10 (note: no colonies detected
in two of three experiments).
Benefits:
 Potential applications in the treatment of cancer of the prostate
 Treatment of dermatological conditions including acne, seborrhea, hirsutism, alopecia, hidradenitis
suppurativa
Patent Status:
The technologies are patented with fully preserved U.S. patent rights available for licensing opportunities.
 U.S. Issued Patent (No. 7,807,713)
 U.S. Issued Patent (No. 7,550,505)
 U.S. Issued Patent (No. 8,450,374)
5
Method to Isolate Peptide from Whey and Milk
(UD07-33)
Technology Description:
A new sulfhydryl oxidase has been isolated from bovine milk whey
and shown to be completely distinct from a metal-dependent
sulfhydryl oxidase previously purified from that source. The newly
recognized milk sulfhydryl oxidase has been identified as a member of
the quiescin-sulfhydryl oxidase (QSOX) family of flavoproteins. Herein
we abbreviate this enzyme as milk-QSOX1. These QSOX enzymes
generates disulfide bonds in a wide range of sulfhydryl compounds
and, importantly, in peptides and reduced unfolded proteins (2). This
new milk-QSOX1 enzyme also has a broad specificity with highest
activity towards unfolded reduced proteins. It is expected to find
utility in applications where the generation of disulfide bonds from
sulfhydryl groups is needed in aqueous systems under mild
conditions.
Benefits:
 Method to isolate a QSOX peptide in high purity from milk
 Method to isolate and partially purify a QSOX polypeptide from
a solution of whey
 Method forms disulfide bonds from sulfhydryl groups in
aqueous solutions
 Method to modify the properties of food such as removal of
undesirable flavors
Patent Status:
The technology is patented with fully preserved U.S.
patent rights available for licensing opportunities.
 U.S. Issued Patent (No. 7,625,733)
Fig. Steps in the mechanism of a
hypothetical flavin-dependent
sulfhydryl oxidase.
6
Novel Tool for Detection of Metastatic Cancer
(UD07-34)
Technology Description:
Bone marrow is contiguous with the circulation, hence biomarkers produced in that tissue compartment
rapidly enter the circulation where they can be detected with appropriate assays. We have identified a
series of novel neoepitopes that can be produced by lysis of the bone marrow extracellular matrix during
tumor cell invasion. Detection of these neoepitopes in circulating fluids can be used to monitor the
activity of invasive bone metastases. Thus the invention can be used to detect metastatic cancers, such as
breast and prostate cancer.
Fig. Rendering of Perlecan
Benefits:
 More sensitive and able to detect bone invasion earlier than previous methods
 Multiplex approach that reduces false positives
 Method to detect metastatic cancers
Patent Status:
The technology is patented with fully preserved U.S. patent rights available for licensing opportunities.
 U.S. Issued Patent (No. 8,481,273)
7
Novel Means for Tyrosine Phosphatase/Kinase Detection in
Therapeutic Application
(UD10-35)
Technology Description:
The invention is a novel means for the fluorescent detection of tyrosine phosphatase and tyrosine kinase,
of interest for therapeutic applications. This approach combines a genetic encodability with the exhibition
of large fluorescence changes upon phosphorylation, enabling practical advantages over previous
tyrosine phosphatase/kinase detection methods. Additionally, this approach is readily applicable to
different kinases and phosphotases through modification of the recognition sequence.
Fig. Large fluorescence changes observed upon phosphorylation enable easier detection
Benefits:




Applicable for in vitro assays, in cell extracts, in tissue extracts, and in living cells
Genetically encodable method
Large fluorescence changes upon phosphorylation
Applicable to tyrosine kinase activity and inhibitors, as well as tyrosine phosphatase activity and
inhibitors
Patent Status:
The technology is patented with fully preserved U.S. patent rights available for licensing opportunities.
 U.S. Issued Patent (No. 8,551,723)
8
Novel Use of Regulatory Platelets for Anti-Thrombotic Drug
(UD11-19)
Technology Description:
The invention provides details on a novel anti-thrombotic drug. Research has indicated the presence of a
protein called ASK1 expressed in platelets, the key players in the pathology of thrombosis. Research has
also indicated that this protein may be the key regulator in platelet function, and thus thrombosis.
Inactivation of this protein has been shown to greatly protect from experimental thrombosis without the
side effect of bleeding. Specifically, it was found to be dynamically initiated during platelet activation. In a
mouse, absence of this protein greatly protects from experimental thrombosis without causing bleeding.
Fig. ASK1 Activation
Benefits:
 Novel drug candidate for anti-thrombotic drugs
 Eliminates the side-effect of bleeding
Patent Status:
The technology is patent pending with fully preserved U.S. patent rights available for
licensing opportunities.
• Published U.S. (No. 2013-0236441)
9
Novel Tool for Enhanced Recombinant Protein Production
(UD11-20)
Technology Description:
Chinese hamster ovary (CHO) cells are the most commonly used mammalian cell line for production of
biopharmaceutical proteins. The recent development of genome-scale technologies permits direct cell
engineering by manipulating single genes that play important roles in metabolic or regulatory pathways
to generate high-producing cell lines. RNA interference (RNAi), induced in mammalian cells via small
interfering RNA duplexes or short hairpin RNA vectors, negatively regulates gene expression in a
sequence-specific manner. This technology is comprised of a method to use RNAi to selectively reduce
levels of an actin cytoskeletal regulatory protein, cofilin 1, to enhance specific productivity of
recombinant proteins in CHO cells.
Fig. Subcellular distribution of
ADF/cofilin proteins in CHO cells. CHOK1 cells were labeled with anti-ADF
and anti-cofilin. CHO-SEAP and CHOtPA cells were labeled with anti-cofilin.
Nuclei were counterstained with DAPI.
Benefits:
In contrast to conventional strategies, the method employed in this invention is a direct cell engineering
approach using RNAi to selectively reduce levels of cofilin 1, a protein that regulates actin cytoskeletal
dynamics. Recombinant protein productivity is enhanced by using RNAi to destabilize the actin
cytoskeleton.
Patent Status:
The technology is patented with fully preserved U.S. patent rights available for licensing
opportunities.
 U.S. Issued Patent (No. 8,722,409)
10
Injectable and Biologically Derived Polymer for Tissue Repair
(UD11-38)
Technology Description:
The proposed technology is an injectable device for the repair of damaged tissue. The device is comprised
of a polymer scaffold coated with synthetic proteoglycans derived from the perlecan of a mouse, rat, or
human. These proteoglycans, with at least one glycosaminoglycan chain attached, retain the ability of
perlecan to bind and present heparin-binding growth factors and to induce or maintain a chondrocyte
phenotype. Growth factors can be attached to the proteoglycans ex vivo, and the resulting product can
be administered to the wounded area.
The technology, involving bio-conjugation of PlnD1 carrying heparan sulfate chains to a biologicallyderived scaffold/polymer for therapeutic delivery of heparin-binding growth factors (HBGFs) and repair
of cartilage tissue is covered under a separate patent- UD01-02 (US 7,875,591 patent entitled “Delivery
System for Heparin-Binding Growth Factor”). The novelty of this technology is that the device is not
implanted but injected for promoting the repair of damaged tissue/organs.
Fig. Studies depicting articular cartilage of knees
treated with PlnD1-HA/BMP2 showed increased
expression of aggrecan relative to control (PlnD1HA or saline) knees after 7 days of treatment.
Benefits:
 Repair of damaged cartilage tissue
 Sustained release of growth factors directly to the wounded area
Patent Status:
The technology is patent pending with fully preserved U.S. patent rights available for licensing
opportunities.
 Published U.S. (No. 2014-0005111)
11
Hydrogel Based Slow Release Drug Delivery Vehicle
(UD12-10)
Technology Description:
The invention provides a means to selectively control the degradation rates of hydrogels and
bioconjugates, such as for drug release in the pharmaceutical industry or implants in the biomaterials
industry. Addition of thiols and maleimides is widely used in preparing biological conjugates and is known
to lead to some product instabilities in vivo, allowing the reverse reaction (retro Michael addition) to
occur. By using a specific thiol in the process, the retro Michael addition can be rendered permanent at
physiological pH and temperature, introducing a novel technique for controlled degradation and release.
Fig. Michael donor reactivity controls conversion under reducing conditions. Therefore,
tuning and triggering of material properties is possible.
Benefits:
 More selective than previous/current technologies
 Chemically versatile
 Cost-effective
Patent Status:
The technology is patent pending with fully preserved U.S. patent rights available for licensing
opportunities.

Published U.S. (No. 2013-0244975)
12
Fast and Low Cost Method for DNA Sequencing
(UD12-17)
Technology Description:
The successful realization of fast and low-cost methods for reading the sequence of DNA bases is
envisaged to lead to personalized medicine and applications in various subfields of genetics. Solidstate nanopores represent one of the pillars of the so-called third generation sequencing. Graphene,
the recently discovered two-dimensional allotrope of carbon whose atoms are densely packed into a
honeycomb lattice, brings its unique electronic and mechanical properties into the search for an
optimal nanoelectronic biosensor. However, the recent experiments on nanopores within single or
multilayer large-area graphene, which have measured fluctuations in the vertical ionic current flow
due to DNA translocation through the pore, have not reached sufficient resolution to detect and
identify individual nucleobases. This invention proposes a novel device concept that could resolve
these issues and provide readings with sufficient resolution to detect and identify individual
nucleobases.
Fig. Schematic view of the proposed
two-terminal device where transverse
conduction current flows mostly
around the zigzag edges of a metallic
graphene nanoribbon with a
nanopore, while DNA molecule is
translocated through the pore to
induce nucleobase-specific
modulation of such edge currents.
Benefits:
 Potential for low cost DNA sequencing
 Method allows readings resolution to detect and identify individual nucleobases
Patent Status:
The technology is patent pending with fully preserved U.S. patent rights available for licensing
opportunities.

Published U.S. (No. 2013-0186758)
13
Salivary Gland Restoration
(UD12-39)
Technology Description:
The invention consists of an implantable, biologically-based, cell seeded 3D implant that will restore
salivary function in patients suffering from xerostomia. Also described is a novel modular approach for
the creation of function salivary cell assemblies that can be co-assembled into a larger hydrogel for direct
implantation into patients. One example of a biomimetic matrix that can be constructed from such an
approach is one composed of hyaluronic acid (HA) that is chemically modified with reactive handles. It is
advantageous to use this HA for in situ cell encapsulation in 3D culture, because it binds specific receptors
that are expressed on salivary glands. Moreover, cell-instructive biological cues can be incorporated into
HA networks using a multiblock alternating copolymer of poly ethylene glycol and a peptide from
perlecan. Growth factors can in turn be incorporated to promote morphogenesis. The proposed method
of action is to isolate salivary gland progenitor cells prior to radiation treatment (known to cause
xerostomia), expand and/or manipulate the cell in vitro, and return them to the site of injury via a
biocompatible implant.
Fig. Strategy for creating salivary cell modules. GF-loaded HGPs will be co-encapsulated within an HA
matrix, crosslinked by an PlnDIV-Peg copolymer to produce microscale Cell-MMs. Multiple Cell-MMs
will then be gelled with angiogenic HGPs to produce a 3D-ST implant.
Benefits:
 Modular approach that is necessary for complex nature of salivary gland regeneration
 Model described can be used for autologous implantation as well as tissue typing and allografting
Patent Status:
The technology is patent pending with fully preserved worldwide patent rights available for
licensing opportunities.
14
Novel Probes with Enhanced Specificity and Sensitivity in
Magnetic Imaging Applications (NMR, MRS,MRI)
(UD13-15)
Technology Description:
Development of new probes to detect specific molecular events associated with disease would
substantially increase the information content of MRI. 19F imaging has enormous potential because of its
specificity (high signal to noise due to the absence of fluorine in vivo, its high sensitivity compared
to proton imaging, and its application using commercial proton magnetic resonance instruments).
The potential of 19F magnetic imaging in medicine is currently substantially limited by a need to
achieve increased sensitivity for applications. An ideal approach to enhance specificity and
sensitivity of 19F magnetic resonance spectroscopy would involve the incorporation of an intense
fluorine signal into native ligands in a manner that is minimally disruptive of structure.
This invention incorporates perfluoro-tert-butyl groups, specifically perfluoro-tert-butyl hydroxyproline,
into peptides as novel amino acids. Perfluoro-tert-butyl groups have 9 equivalent fluorines, and thus
have a 9-fold increase in signal-to-noise over single fluorines. At least as importantly, perfluoro-tertbutyl groups are sharp singlets by NMR, further increasing signal-to-noise and operational simplicity,
meaning that most existing proton-based instrumentation can be readily adjusted to detect peptides
containing perfluoro-tert-butyl groups. Because of its high signal-to-noise ratio and the ability to be
incorporated within peptides and proteins, perfluoro-tert-butyl hydroxyproline has broad
potential applications in magnetic imaging (NMR, MRS, MRI), both in vitro and in vivo. Tert-butyl
groups also have broad importance in medicinal chemistry due to their hydrophobicity and
symmetry, leading to enhanced binding to targets.
Fig. Full NMR spectrum of peptide
Ac-TYP(4R-OC(CF3)3)N-NH2.
Benefits:




Enhanced specificity and sensitivity in magnetic imaging (NMR, MRS, MRI)
High signal-to-noise ratio for clearer and more precise outputs
Hydrophobicity and symmetry of groups enhance binding to target molecules
High sensitivity and affinity for improved biomarker detection
Patent Status:
This technology is patent pending with fully preserved worldwide patent rights available for
licensing opportunities.
15
Sensole Shoe: A Device for Measuring Gait in Parkinson’s
Disease Patients
(UD13-30)
Technology Description:
SEnsole is a stand-alone shoe insole device that measures gait characteristics and mobility of an individual
(people who are healthy and those with chronic disease) in their home and in community settings.
Parkinson’s and stroke patients often have trouble with ambulation. This invention is an untethered shoe
insole device that measures gait characteristics and mobility of a patient in their home and community
setting. The device includes rate gyros (angular acceleration sensors), tri-axial accelerometers, and an
altimeter. Gait and mobility data is transmitted wirelessly over a personal area network to a notebook
computer.
Benefits:
 Can measure gait and mobility of Parkinson’s and stroke patients 24/7 in the home and community
environment
 Untethered. Insole fits inside a patient’s shoe
 Four ground-foot interaction forces (heal, lateral ball, medial ball, and first toe)
 Includes six-axis gyro and accelerometer sensor
Uses/Users:
 Clinicians seeking to monitor the gait fluctuations of patients 24/7
 Patients with Parkinson’s, stroke, and other neuropathic diseases
Patent Status:
The technologies are patent pending with fully preserved U.S and worldwide patent rights available for
licensing opportunities.
16
Modular Steering and Braking System for Commercial
Bicycle or Tricycle
(UD13-42)
Technology Description:
Rehab and physical therapy clinics all over the world are searching for innovative, safe ways to
rehabilitate their patents and integrate them into society. This new, creative design for a bicycle allows
disabled individuals to enjoy the pleasures of riding a bike with their loved ones. The systems that are
displayed here permit the steering and stopping of a bicycle, via a switch or joystick control. The modular
steering and braking systems are mechanical components that can be added to any commercial bicycle or
tricycle and allow the user to remotely control the steering and braking systems, respectively. These are
add-on components, and the bike frame does not need to be altered or dismantled to include the
systems. The modular steering system is a motor-driven assembly that mounts to a bicycle stem and
overrides hand-controlled steering. Similarly, the modular braking system is motor-driven and mounted
to the bike frame and grips the cable brakes, overriding hand-controlled braking.
Benefits:
 Permits steering and braking via on-off switch or joystick hand controls
 Enables disabled individuals who lack the motor control to perform steering and braking on a
conventional bicycle or tricycle
Uses/Users:
 Add-on kits sold to major bicycle manufacturers
 Manufacturers of modular bicycle motors
 Disabled individuals who may benefit from modular steering and braking systems
Patent Status:
The technologies are patent pending with fully preserved U.S and worldwide patent rights available for
licensing opportunities.
17
Sit-Stand-Power Walker for Early-Aged Developing Children
With Mobility Impairments
(UD13-47)
Technology Description:
The invention is a light weight, electric powered, 3-4 wheeled mobility device (aka “car”) to be used as a
toy, power wheelchair, and/or exercise equipment for early-aged developing children with mobility
and/or cognitive impairments. The device has multiple functions which are related to its ability to be
driven from three different body positions: seated, standing, and walking. The device can be driven
while seated, then with small/quick adaptations can be driven from a standing position, then with
small/quick adaptations can be driven while the child also has his/her feet on the ground and is walking
(aka “power assisted walking”).
Benefits:




Provides fun activity as a result of movement and mobility
Enhances exercise and development in children with exceptionalities
Provides functional skill training (sitting, standing, walking)
Promotes play (aka “Participation” or “Socialization”) with other children
Uses/Users:
 Children aged 0-3 years of age with mobility and/or cognitive impairments
 Clinical rehabilitation labs, educational classroom, as well as at-home 24/7 use
Figure 1. Modified cars activated in sitting, by standing up (note switch on the seat and elevated
steering extension) and by walking (switch hidden under the seat). PVC tubing in standing car and
powered walker strong enough for body weight support harness (not shown).
Patent Status:
The technologies are patent pending with fully preserved U.S and worldwide patent rights available for
licensing opportunities.
18
VidaVest: A Chest Compression Simulation Device for Improved
Cardiopulmonary Resuscitation Training
(UD14-06)
Technology Description:
With regard to understanding the gravity of a Code Blue situation, using live actors in simulation labs is
preferred over using mannequins. However, mannequins are used exclusively in Code Blue, or cardiac
arrest simulations due to the risk of injury to a live actor during chest compressions. Some simulation labs
use mixed models, but there is a large disconnect in the time that the CPR performer must switch from
the actor to the mannequin to initiate chest compressions. This invention was designed from a need for a
device that could be worn by an actor while allowing the user to perform chest compressions both
accurately and realistically during both simulation labs and CPR training sessions.
VidaVest is a wearable chest compression simulation device that gives real-time biofeedback information
to the user. It is composed of a skin overlay molded from a human chest, a deflection mechanism of three
volute springs in parallel, a metallic sternum with a thin end that moves through a channel of infrared
sensors to detect compression depth, and an aluminum chest plate with a foam layer underneath for
added comfort. VidaVest is complete with adjustable straps for wearers of any size, an LCD display for
visualizing compression depth, a metronome for the user to maintain the correct compression rate, and
nipples on the skin overlay to indicate proper hand placement for compressions.
The safety of VidaVest was validated with force–displacement analyses, and feedback from UD’s Nursing
Program supported the benefits of VidaVest in terms of real-time biofeedback output, aesthetics, and
simplicity. VidaVest makes nursing simulation labs more realistic during Code Blue reenactments with the
anatomical landmarks on its skin overlay, the stiffness of its deflection mechanism, and its ability to be
worn by people of varying sizes. The device’s biofeedback output gives users a better idea of how deep
their compressions are so that inappropriate compressions can be corrected immediately. Overall,
VidaVest is a major improvement in simulation labs as an effective and versatile learning tool for CPR.
Fig. Lateral view of VidaVest on left,
superior view of VidaVest on right.
Benefits:
 Improved training for healthcare providers to attend patients in cardiac arrest
 Real-time patient feedback
 Interactive learning experience to make scenarios more realistic as opposed to use of computerprogrammed mannequins
Patent Status:
The technologies are patent pending with fully preserved U.S and worldwide patent rights available for
19
licensing opportunities.
Tracheostomy Overlay for Educational Simulation
(UD14-07)
Technology Description:
This invention is an ‘overlay’ that is applied to actors who play the role of a patient in simulation training.
The overlay will consist of a partial tracheostomy tube and a skin-like material that will make the actor
wearing the overlay appear as a true tracheostomy patient. The overlay will also have embedded in it a
biofeedback system that will alert the student in training whether he or she is using proper technique in
manipulating the tracheostomy tube. This tool will enhance care for tracheostomy patients through
effective educational simulation.
The human respiratory system requires inspired air to enter the body through the mouth or nose, then
pass to the trachea, bronchi, bronchioles, and lung tissue where the oxygen is exchanged for carbon
dioxide at the capillary level. There are some diseases that require the air to bypass the mouth and nose
and enter through the trachea (tracheostomy). These patients have a one-inch incision just below the
Adam’s apple where a small device is inserted to keep the stoma from closing up (tracheostomy tube;
figure below). These patients are challenging for healthcare providers to speak with, care for, and assess
for complications. Because of these challenges, it is imperative that educational institutions provide safe
simulated learning modules that include patients with a tracheostomy.
Fig. Diagram of a tracheostomy tube that creates an opening in the
respiratory channel.
Benefits



Improved training for healthcare providers to attend patients with tracheostomy
Real-time patient feedback
Interactive learning experience to make scenarios more realistic as opposed to use of computerprogrammed mannequins
Patent Status:
The technologies are patent pending with fully preserved U.S and worldwide patent rights available for
licensing opportunities.
20
QuadCrew Recoil Rowing System
(UD14-09)
Technology Description:
This system replaces a standard oar in a sweep style crew shell with a paddle wheel system driven by a
recoil mechanism. The recoil mechanism is actuated by the user pulling linearly on a handle/strap. The
strap’s linear motion is translated to rotational motion via a pulley system connected to a rotating bar.
The rotating bar is connected via a gear/chain to another axel. On the end of this axel is a paddle wheel
that sits in the water. This drives the boat forward. The pulleys are used to manage the strap and control
the motion of the recoil mechanism that allows the strap to recoil as the user moves forward towards the
pulley. The paddle wheel will eventually be enclosed in a fender to prevent the user from being splashed.
All parts of the system attach to the shell using the holes already in place for the outriggers.
This recoil rowing system is designed to be used by a variety of disabled users who wish to row in a
sweep style crew boat. Standard oar rowing requires a very dynamic stroke that is impossible for disabled
users with no fine motor control or a lack of upper body control. The advantage of using a linear-pull
cable is that the propulsion motion is reduced from the dynamic oar stroke to a simple linear pull,
allowing for many different types of people to participate with a team of standard able-bodied rowers.
For example, an armless or hand-less user could have the cord tied to the seat and perform the work with
his or her legs. Users with neurological conditions, such as multiple sclerosis, do not need fine motor
control to operate this system. If the user cannot grip the handle of the pull cord, weight-lifting hooks can
be attached to the user’s wrists to aid the user in grasping the handle of the QuadCrew Recoil Rowing
System.
Fig. Working system prototype with components labeled.
Benefits:


Allows disabled people to be actively engaged in a sporting event
Gives disabled people the opportunity to row with able-bodied athletes
Patent Status:
The technologies are patent pending with fully preserved U.S and worldwide patent rights available for
licensing opportunities.
21
Activity-Based Diubiquitin Probes for Elucidating the Linkage
Specificity of Deubiquitinating Enzymes
(UD14-21)
Technology Description:
Deubiquitinating enzymes (DUBs) are the catalytic proteins responsible for cleaving target ubiquitin
domains from proteins tagged to be degraded by one of many possible cellular processes. Typically, DUBs
interact with ubiquitin probes through their active site, which is characterized by a cysteine residue. The
use of diubiquitin probes (diUbs) as opposed to monoubiquitin probes is favored because the presence of
an ubiquitin acceptor protein allows researchers to determine chain linkage- and target-specificity of
DUBs. This particular invention mimics the native diUb in structure and size but differs by incorporating a
Michael addition acceptor where the peptide bond would normally be located. The alkene acceptor can
“trap” the cysteine thiol of the DUB for improved specificity labeling and subsequent understanding of
cellular processes.
This class of DUB probes will also facilitate the development of more specific inhibitors against the large
number of DUBs that are expected to possess chain- or target specificities. This approach can be used to
generate diUb probes with several different lysine (K) linkages as well as polyubiquitin chain-based
probes. This technology can also be applied to generate probes based on ubiquitinated proteins such as
PCNA, histone, α-synuclein and many other human proteins.
Fig. Preparation and characterization of K63C- and
K48C-diUb probes. (A) Preparation of diUb probes. (B)
Denaturing SDS-PAGE gel showing the formation
of the K63C- and K48C-diUb probes.
Benefits:
 Higher specificity of diUb probe for DUB
 Improved method for understanding cellular processes
involving DUBs
 Simple chemical manufacturing process of probes
 Potential for additional applications using other
ubiquitinated proteins
Patent Status:
The technologies are patent pending with fully preserved U.S and worldwide patent rights available for
licensing opportunities.
22
QuadCrew Seat Motion Syncing Straps
(UD14-25)
Technology Description:
Existing adaptive rowing technology is limited in that it includes a stationary seat used in one-man or twoman sculling shells. These systems cater to users who, at minimum, have arm and shoulder function. No
adaptive technology, recreational or competitive, exists for sweep-style rowing or for the use of a sliding
rowing seat. This invention syncs the motion of three rowers’ moving seats in a standard crew boat. Syncing
their motion is imperative in order to avoid interference between rowers. The QuadCrew Seat Motion
Syncing Straps attach to three adjacent standard crew boat seats by wrapping around the seat top and under
the seat between the seat bottom and the seat undercarriage. The straps fasten with buckles and are
adjustable to allow for users with different leg lengths. The front rowers’ motion defines the other rowers’
backward motion and the back rowers’ motion defines the other rowers’ forward motion.
This motion syncing system has a few uses. First, it can be used independently for novice or unskilled rowers
who want to focus their attention on oar rowing. The syncing straps sync up the motion of the attached
rowers without effort and allow the users to focus their energy on mastering oar rowing before learning
about seat motion syncing. The system can also be used for a team of two able-bodied rowers and a disabled
third rower. When the disabled user is seated in between the two able-bodied rowers, the able-bodied
rowers can guide the motion of the disabled user. Their assistive motion accounts for the disabled user’s lack
of lower body function.
Fig. Leg motion prototype in a crew boat
(left) and attached to a seat (right).
Benefits:



Gives adaptive rowers ability to participate in rowing sport
Offers practice with oar rowing
Inexpensive
Patent Status:
The technology is patent pending with fully preserved U.S and worldwide patent rights available for licensing
opportunities.
23
QuadCrew Adaptive Rowing Seat for Person with Physical Disabilities
(UD14-26)
Technology Description:
Existing adaptive rowing technology is limited in that it includes a stationary seat used in one-man or twoman sculling shells. These systems cater to users who, at minimum, have arm and shoulder function. No
adaptive technology, recreational or competitive, exists for sweep-style rowing or for the use of a sliding
rowing seat. The QuadCrew Adaptive Rowing Seat provides adjustable back, neck/head and arm support
to rowers with physical disabilities as limiting as quadriplegia. It rolls on the standard tracks of a crew
boat shell, like any standard crew seat would. The arm supports can be flipped up and out of the way for
accessibility to the seat from the side of the boat and can be adjusted in two dimensions to fit users with
different heights and body widths. The neck/head support is also adjustable in two dimensions and can
be removed when not in use. The back support is outfitted with a torsion spring to allow the user to lean
back (if their mobility allows) when rowing and extend to the best of their ability.
The design is based off of designs found in wheelchairs and reclining desk chairs so that adaptive rowing
can serve a larger community of people. Currently, adaptive rowing seats for recreational and Paralympic
use are fixed in the boat and can only be used by rowers with strong upper body ability. The angle of the
lean back mechanism was evaluated using image processing to determine the optimal torsion spring and
maximum angle the user can lean.
Fig. Adaptive seat prototype in three views.
Benefits:



Gives adaptive rowers ability to participate in rowing sport
Provides comfort to user
Adjustable for users with differing support needs
Patent Status:
The technology is patent pending with fully preserved U.S and worldwide patent rights available for
licensing opportunities.
24
Playskin™ Lift: Assistive Garments for Young Infants With Weakness or
Movement Problems
(UD14-27)
Technology Description:
For individuals with weakness and/or movement impairments, these garments can be used to assist
functioning and as rehabilitative devices to minimize impairments across time. Populations that could benefit
from this type of device include: infants with brachial plexus palsy (nerve damage to one arm at birth), infants
born preterm, infants with Down syndrome, children with cerebral palsy, individuals with hemiplegia due to
cerebral palsy or stroke, individuals with arthrogryposis multiplex congenita, individuals with Duchenne’s
Muscular Dystrophy, and individuals with spinal muscular atrophy.
Playskin LiftTM is a garment that provides varying levels of assistance to young infants who cannot yet reach
and to individuals with weakness and/or movement problems with their arms. It is a soft, comfortable,
attractive, wearable garment that incorporates stiff yet flexible components to help support the arms lifted
against gravity. This allows users to interact with objects in front of them for important tasks such as eating,
playing, writing, and doing computer work.
The Playskin LiftTM is the most fully developed model of the PlayskinTM series of garment-based orthoses. The
initial prototype for this device has been fabricated and is already being tested. The mechanisms being
utilized to assist anti-gravity arm support in these initial prototypes include the use of flexible metal
components run in parallel and held together by a sheath to create friction among the components and
custom designed air pockets users can actively control to inflate and lift or deflate and lower the limbs. The
PlaySkin LiftTM Garment uses piano cables cut to the appropriate length and run in parallel. The cables are
then compressed and held together by a soft heat shrunk material. The result is an insert that fits into a
tunnel built in a garment that runs under the arm, below the armpit, and down the side of the rib cage. The
cables themselves are flexible but also elastic so when they bend under the weight of the limb, they want to
return to their original shape so they provide anti-gravity lift to the arm. Variable inserts have different colors
of wrap to designate ones with progressively more cables to provide more lift (for more assistance or for
large arms). Therefore, one can adjust the level of assistance by switching the insert.
Fig. Child with arthrogryposis multiplex
congenita with apparent limited limb
mobility.
Benefits:



Gives disabled children ability to use affected limbs
Inexpensive manufacturing process
Less bulky than established garments
Patent Status:
The technology is patent pending with fully preserved U.S and worldwide patent rights available for licensing
opportunities.
25
Multimode Degradable Hydrogels For Controlled Therapeutic
Release
(UD14-40)
Technology Description:
This invention describes the use of a responsive hydrogel-based material as a carrier system for in situ
delivery of various bioactive moieties, including small molecules, biomolecules, biomacromolecules
(including, but not limited to polysaccharides, glycosaminoglycans, proteins), and cells. The novel
chemistries presented will enable finely tuned local release of cargo molecule(s) and material
constituents as a function of the in-vivo tissue environment (e.g., enzyme concentration or reducing
environment) and externally applied stimuli (e.g., light) by selective spatiotemporal hydrogel
degradation.
Fig. Release of encapsulated BSA was monitored using fluorescence spectrometry. Significant differences
in release kinetics correlate with the degradation profile of D2 hydrogel, which can be attributed to
retro and exchange reactions.
Benefits:
• Local controlled therapeutic release for increased efficacy with reduced side effects
• Ability to tune the degradation and release of cargo molecules
Uses/Users:
• Therapeutics, wound healing patches, tissue engineering scaffolds, barriers for tissue injury healing, cell
encapsulation platform, implant coatings, etc.
Patent Status:
The technology is patent pending with fully preserved U.S. and worldwide patent rights available for
licensing opportunities.
26
IPTB, a novel apoptosis signal-regulating kinase (ASK1) inhibitor
as anti-thrombotic drug
(UD14-50)
Technology Description:
Platelets are small anucleate blood cells, which are activated upon vessel wall damage and aggregate to
form a platelet plug in order to prevent bleeding. However, inappropriate activation of platelets under
certain pathological conditions such as atherosclerotic plaque rupture results in formation of occlusive
thrombi, which could result in myocardial infraction or stroke. The current available pharmacological
agents are not effective in all the patients and often cause side effects such as bleeding or hemorrhage.
Mitogen activated protein (MAP) kinases have been shown to be activated downstream of a variety of
platelet agonist receptors and contribute significantly to the physiological function of platelets. Apoptosis
Signal-regulated Kinase 1 (ASK1), belonging to MAP3K family have been successfully identified as a novel
platelet protein which is rapidly activated during platelet stimulation by a variety of platelet agonists.
Genetic ablation of ASK1 results in a strong anti-thrombotic phenotype in an array of in vivo models of
thrombosis, which is found to be due to reduced platelet reactivity.
This invention describes a novel chemical compound of small molecular weight (IPTB), which has proven
to be a successful ASK1 inhibitor and therefore, inhibiting platelet formation in vitro and thrombosis in
vivo. It also has potential therapeutic use in a variety of diseases such as deep vein thrombosis,
myocardial infraction, stroke, pulmonary embolism, atherosclerosis, and Parkinson’s disease.
Figure: Confocal images of IPTB treated human platelet
Benefits:
• IPTB is highly potent.
• It has advantage over existing anti-thrombotic drugs since it can inhibit thrombosis without causing
bleeding.
Uses/Users:
• IPTB can be used as an inhibitor of thrombosis, Parkinson’s disease and many other associated
diseases.
Patent Status:
The technology is patent pending with fully preserved U.S. and worldwide patent rights available for
licensing opportunities.
27
For Further Information
Please Contact:
Denise M. Bierlein
Telephone: (302) 831-4005
Email: techtransfer@udel.edu
Mailing Address
University of Delaware
Office of Economic Innovation & Partnerships
1 Innovation Way, Suite 500
Delaware Technology Park
Newark, DE 19711